相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1856
已完成
4
100.0%
暂无批准数据
- A JAMA Network Open study comparing Reddit menopause discussions with over 2 million UCSF electronic health record notes found emotional symptoms discussed online nearly three times as often as in clinical records. - Cognitive symptoms such as brain fog, memory problems, and word-finding difficulty appeared online nearly four times as often as in clinical records, revealing a systematic documentation gap. - Women report rage, panic, and mood shifts being mislabeled as primary psychiatric conditions, leading to unnecessary antidepressant prescriptions and months or years of unnecessary testing. - Researchers argue that because undocumented symptoms are not studied, the next generation of guidelines and drug trials risks being built on an incomplete record of the menopause experience.
- Vibrio vulnificus infections are moving northward along the U.S. Atlantic Coast at approximately 30 miles per year, with the northern boundary now reaching as far as Maine. - The CDC estimates approximately 80,000 vibriosis cases occur annually in the U.S., with vulnificus carrying a fatality rate of 15–50% depending on exposure route and patient health. - University of Florida researchers are developing a predictive model that can forecast high-risk coastal counties one month in advance, capturing 72% of cases in recent test runs. - Hurricane-driven flooding in 2022 and 2024 pushed brackish water inland, leading to 17 and 19 vulnificus deaths in Florida respectively, underscoring the link between extreme weather and infection spikes.
- The FDA has granted Fast Track designation to CS-1103, a first-in-class small molecule developed by Clear Scientific for treating acute fentanyl intoxication. - CS-1103 works by binding and encapsulating intoxicants in the blood to rapidly reverse toxic effects and accelerate clearance into urine. - The injectable therapeutic demonstrated safety and tolerability in Phase 1 trials, with Phase 2 trials for fentanyl expected to begin in June 2026. - The designation addresses a critical unmet need in the opioid crisis, which causes 2,500 emergency department visits and 150 deaths daily in the US.
- ENA Respiratory has dosed the first participants in its Phase II POSITS study evaluating INNA-051, a virus-agnostic nasal spray designed to prime natural antiviral defenses against respiratory infections. - The study will recruit up to 1,100 participants at high risk for viral exposure, with an initial 200-participant safety phase followed by a 900-participant efficacy phase next season. - INNA-051 targets toll-like receptor 2/6 and has demonstrated accelerated virus clearance in previous Phase IIa studies using human influenza-challenge models. - The therapy aims to address a significant unmet need, as respiratory viral infections caused over one million hospitalizations and up to 200,000 deaths in the U.S. in 2025.
- A new study published in Cell challenges the traditional understanding of how ADHD medications like Adderall and Ritalin work, showing they primarily target brain regions involved in wakefulness and reward rather than attention circuits. - Researchers analyzed brain scans from 5,795 children and found that stimulants enhance performance by making individuals more alert and interested in tasks, producing brain activity patterns similar to quality sleep. - The findings suggest that improved attention is a secondary effect of increased alertness and motivation, which could help clinicians better explain how these medications work to patients and families. - The study emphasizes the importance of adequate sleep for ADHD management and may eventually lead to brain scan-based methods for confirming ADHD diagnosis and predicting treatment response.
- An oral live-attenuated vaccine CVD 1902 showed 73% efficacy against Salmonella Paratyphi A infection in a phase 2b human challenge trial involving 72 healthy UK adults. - The vaccine represents the first modern-day vaccine proven to protect against S. Paratyphi A, which causes more than 2 million cases of enteric fever annually with no currently available vaccine. - The double-blind, randomized trial found only 21% of vaccinated participants developed infection compared to 75% in the placebo group following deliberate exposure to the pathogen. - The vaccine demonstrated a favorable safety profile with no serious vaccine-related adverse events and induced strong serum IgG and IgA antibody responses to the O antigen.
- An Oxford University-led phase 2b trial demonstrated that oral live-attenuated vaccine CVD 1902 achieved 73% efficacy against Salmonella Paratyphi A infection in healthy adults. - The controlled human infection study enrolled 72 participants, with only 21% of vaccinated individuals developing infection compared to 75% in the placebo group. - This represents the first modern vaccine to show protection against paratyphoid fever, a disease affecting over 2 million people annually with no currently available vaccine. - The vaccine showed no safety concerns and only mild to moderate side effects, marking a significant step toward controlling enteric fever in resource-poor regions.
- Humacyte published outcomes in the Journal of Vascular Surgery showing Symvess achieved 92% patency rates and 100% limb salvage in 12 patients with hospital-acquired vascular complications. - The bioengineered vessel demonstrated zero cases of conduit infection over an average follow-up period of 23.3 months in patients requiring arterial repair. - Hospital-acquired vascular complications comprise nearly 30% of patients requiring vascular repair, representing a significant unmet medical need in emergency surgical settings. - Symvess offers an off-the-shelf alternative to autologous vein grafts, eliminating the need for additional surgical procedures to harvest patient vessels.
- Cornell researchers have bioengineered bacteria with a unique enzyme from Desulfovibrio marinus to attach glycans to monoclonal antibodies, potentially democratizing access to therapeutic antibody drugs. - The breakthrough addresses a key limitation of bacterial production systems by enabling protein glycosylation, which impacts over 50% of human proteins and is critical for antibody immune function. - The engineered E. coli bacteria could offer dramatically accelerated production speeds and significantly lower costs compared to conventional Chinese hamster ovary cell manufacturing methods. - The technology could enable production of antibody drugs for cancer, autoimmune, and infectious diseases, though optimization for higher production titers remains necessary.
- The Maryland Stem Cell Research Commission has awarded over $18 million in grants to 52 investigators working on nearly 50 different medical conditions including sickle cell anemia, diabetes, and various neurological disorders. - Funding recipients include innovative companies like Seraxis Inc. and Britecyte Inc., alongside researchers from major Maryland institutions, with the University of Maryland Eastern Shore receiving its first-ever stem cell research grant. - Since its establishment in 2006, the MSCRF has invested over $200 million in more than 650 projects, generating $525 million in economic activity and creating over 2,000 jobs across Maryland.
